IL112521A - Formulation comprising a paroxetine-amberlite irp 88 complex pharmaceutical compositions containing same and uses thereof - Google Patents
Formulation comprising a paroxetine-amberlite irp 88 complex pharmaceutical compositions containing same and uses thereofInfo
- Publication number
- IL112521A IL112521A IL11252195A IL11252195A IL112521A IL 112521 A IL112521 A IL 112521A IL 11252195 A IL11252195 A IL 11252195A IL 11252195 A IL11252195 A IL 11252195A IL 112521 A IL112521 A IL 112521A
- Authority
- IL
- Israel
- Prior art keywords
- paroxetine
- formulation
- pharmaceutical compositions
- compositions containing
- containing same
- Prior art date
Links
- 229920001429 chelating resin Polymers 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9402029A GB9402029D0 (en) | 1994-02-03 | 1994-02-03 | Novel formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL112521A0 IL112521A0 (en) | 1995-05-26 |
| IL112521A true IL112521A (en) | 1999-09-22 |
Family
ID=10749765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11252195A IL112521A (en) | 1994-02-03 | 1995-02-02 | Formulation comprising a paroxetine-amberlite irp 88 complex pharmaceutical compositions containing same and uses thereof |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5811436A (cs) |
| EP (1) | EP0742715B1 (cs) |
| JP (1) | JP4445590B2 (cs) |
| CN (1) | CN1074922C (cs) |
| AP (2) | AP611A (cs) |
| AT (1) | ATE178489T1 (cs) |
| AU (1) | AU682091B2 (cs) |
| BG (1) | BG62843B1 (cs) |
| BR (1) | BR9507055A (cs) |
| CA (1) | CA2182593A1 (cs) |
| CZ (1) | CZ285128B6 (cs) |
| DE (1) | DE69508924T2 (cs) |
| DK (1) | DK0742715T3 (cs) |
| DZ (1) | DZ1850A1 (cs) |
| ES (1) | ES2129806T3 (cs) |
| FI (1) | FI118205B (cs) |
| GB (1) | GB9402029D0 (cs) |
| GR (1) | GR3030131T3 (cs) |
| HU (1) | HUT75941A (cs) |
| IL (1) | IL112521A (cs) |
| MA (1) | MA23441A1 (cs) |
| MX (1) | MX9603203A (cs) |
| MY (1) | MY113036A (cs) |
| NO (1) | NO307954B1 (cs) |
| NZ (1) | NZ278891A (cs) |
| OA (1) | OA10446A (cs) |
| PL (1) | PL178331B1 (cs) |
| RO (1) | RO116342B1 (cs) |
| RU (1) | RU2136281C1 (cs) |
| SK (1) | SK281214B6 (cs) |
| TW (1) | TW436296B (cs) |
| WO (1) | WO1995020964A1 (cs) |
| ZA (1) | ZA95776B (cs) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
| US6638948B1 (en) * | 1996-09-09 | 2003-10-28 | Pentech Pharmaceuticals, Inc. | Amorphous paroxetine composition |
| ES2155995T3 (es) * | 1997-06-10 | 2001-06-01 | Synthon Bv | Compuestos de 4-fenilpiperidina. |
| US6699882B2 (en) | 1998-03-24 | 2004-03-02 | Smithkline Beecham P.L.C. | Paroxetine compositions |
| DK172860B1 (da) * | 1998-03-25 | 1999-08-16 | Pharmacosmos Holding As | Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman |
| CH689805A8 (fr) * | 1998-07-02 | 2000-02-29 | Smithkline Beecham Plc | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. |
| GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
| US6660298B1 (en) * | 2000-07-27 | 2003-12-09 | Pentech Pharmaceuticals, Inc. | Paroxetine tablets and capsules |
| US6720003B2 (en) | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
| DE60232290D1 (de) * | 2001-04-09 | 2009-06-25 | Rohm & Haas | Kontrollierte Auflösung von Wirkstoffen |
| US20020176842A1 (en) * | 2001-04-09 | 2002-11-28 | Lyn Hughes | Extended release of active ingredients |
| US6906206B2 (en) * | 2001-04-30 | 2005-06-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene |
| GB0119467D0 (en) * | 2001-08-09 | 2001-10-03 | Smithkline Beecham Plc | Novel compound |
| US20040242497A1 (en) * | 2001-08-09 | 2004-12-02 | Barges Causeret Nathalie Claude Marianne | Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt |
| US6939877B2 (en) * | 2002-09-12 | 2005-09-06 | Wyeth | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans |
| US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
| US20050266082A1 (en) * | 2004-05-26 | 2005-12-01 | Patel Satishkumar A | Preparation of stable paroxetine HC1 ER tablets using a melt granulation process |
| WO2006018318A1 (en) * | 2004-08-18 | 2006-02-23 | Synthon B.V. | Liquid paroxetine compositions |
| EP1791531A1 (en) * | 2004-08-20 | 2007-06-06 | Alpharma, Inc. | Paroxetine formulations |
| KR100672184B1 (ko) * | 2004-09-21 | 2007-01-19 | 주식회사종근당 | 파록세틴의 콜린산 또는 콜린산 유도체 염 |
| CA2629514A1 (en) * | 2005-11-14 | 2007-05-24 | Auspex Pharmaceuticals, Inc. | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| CN102430122A (zh) * | 2005-12-13 | 2012-05-02 | 量子高科（北京）研究院有限公司 | 盐酸氟西汀口腔崩解片及其制备方法 |
| FR2912057B1 (fr) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine |
| TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
| US20100273822A1 (en) * | 2009-04-22 | 2010-10-28 | William Wayne Howard | Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins |
| WO2010150219A1 (en) * | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof |
| US8187617B2 (en) * | 2009-09-11 | 2012-05-29 | William Wayne Howard | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments |
| PL2572717T3 (pl) | 2010-05-19 | 2016-12-30 | Kompozycja farmaceutyczna zawierająca solifenacynę | |
| CN104027306A (zh) * | 2014-06-25 | 2014-09-10 | 万特制药(海南)有限公司 | 帕罗西汀口服混悬液及其制备方法 |
| GB201419261D0 (en) | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| CN104382870A (zh) * | 2014-10-30 | 2015-03-04 | 万全万特制药江苏有限公司 | 一种含有波拉克林钾-帕罗西汀的复合物 |
| CN106309363A (zh) * | 2016-09-24 | 2017-01-11 | 万特制药(海南)有限公司 | 盐酸帕罗西汀口服混悬液及其制备方法 |
| CN108926528A (zh) * | 2017-05-25 | 2018-12-04 | 北京万全德众医药生物技术有限公司 | 含有氨磺必利树脂酸盐的口服液体组合物 |
| EP3917523B1 (en) | 2019-02-01 | 2024-09-11 | University of South Carolina | Bicyclic pyridine compounds for use in treating cancer |
| CN113209017B (zh) * | 2021-06-02 | 2023-06-20 | 上海美优制药有限公司 | 一种盐酸帕罗西汀混悬剂及其制备方法 |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| GB2636182A (en) | 2023-12-04 | 2025-06-11 | Novumgen Ltd | An orally disintegrating tablet of paroxetine and its process of preparation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| DE3688827T2 (de) * | 1985-10-25 | 1994-03-31 | Beecham Group Plc | Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel. |
| GB9005498D0 (en) * | 1990-03-12 | 1990-05-09 | Beecham Group Plc | Composition |
| IT1246188B (it) * | 1990-07-27 | 1994-11-16 | Resa Farma | Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute. |
-
1994
- 1994-02-03 GB GB9402029A patent/GB9402029D0/en active Pending
-
1995
- 1995-01-27 MY MYPI95000223A patent/MY113036A/en unknown
- 1995-01-30 WO PCT/EP1995/000319 patent/WO1995020964A1/en active IP Right Grant
- 1995-01-30 ES ES95906998T patent/ES2129806T3/es not_active Expired - Lifetime
- 1995-01-30 CZ CZ962293A patent/CZ285128B6/cs unknown
- 1995-01-30 CA CA002182593A patent/CA2182593A1/en not_active Abandoned
- 1995-01-30 MX MX9603203A patent/MX9603203A/es unknown
- 1995-01-30 SK SK1004-96A patent/SK281214B6/sk unknown
- 1995-01-30 EP EP95906998A patent/EP0742715B1/en not_active Expired - Lifetime
- 1995-01-30 US US08/682,799 patent/US5811436A/en not_active Expired - Lifetime
- 1995-01-30 AP APAP/P/1996/000839A patent/AP611A/en active
- 1995-01-30 DE DE69508924T patent/DE69508924T2/de not_active Expired - Lifetime
- 1995-01-30 HU HU9602151A patent/HUT75941A/hu unknown
- 1995-01-30 RO RO96-01580A patent/RO116342B1/ro unknown
- 1995-01-30 CN CN95191483A patent/CN1074922C/zh not_active Expired - Fee Related
- 1995-01-30 BR BR9507055A patent/BR9507055A/pt not_active IP Right Cessation
- 1995-01-30 AT AT95906998T patent/ATE178489T1/de active
- 1995-01-30 NZ NZ278891A patent/NZ278891A/en not_active IP Right Cessation
- 1995-01-30 RU RU96117470/14A patent/RU2136281C1/ru not_active IP Right Cessation
- 1995-01-30 JP JP52037095A patent/JP4445590B2/ja not_active Expired - Lifetime
- 1995-01-30 AU AU15368/95A patent/AU682091B2/en not_active Expired
- 1995-01-30 DK DK95906998T patent/DK0742715T3/da active
- 1995-01-30 PL PL95315679A patent/PL178331B1/pl not_active IP Right Cessation
- 1995-02-01 AP APAP/P/1995/000715A patent/AP536A/en active
- 1995-02-01 ZA ZA95776A patent/ZA95776B/xx unknown
- 1995-02-01 MA MA23768A patent/MA23441A1/fr unknown
- 1995-02-01 DZ DZ950010A patent/DZ1850A1/fr active
- 1995-02-02 IL IL11252195A patent/IL112521A/xx not_active IP Right Cessation
- 1995-02-09 TW TW084101235A patent/TW436296B/zh active
-
1996
- 1996-08-01 FI FI963051A patent/FI118205B/fi not_active IP Right Cessation
- 1996-08-01 BG BG100763A patent/BG62843B1/bg unknown
- 1996-08-02 NO NO963244A patent/NO307954B1/no not_active IP Right Cessation
- 1996-08-02 OA OA60873A patent/OA10446A/en unknown
-
1999
- 1999-04-30 GR GR990401213T patent/GR3030131T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL112521A (en) | Formulation comprising a paroxetine-amberlite irp 88 complex pharmaceutical compositions containing same and uses thereof | |
| HUS1200028I1 (hu) | 4"-Szubsztituált-9-dezoxo-9a-aza-9a-homoeritromicin-származékok és ezeket tartalmazó gyógyszerek | |
| IL114622A0 (en) | Heteroaryl-oxazolidinones and pharmaceutical compositions containing them | |
| IL114759A (en) | Benzoxazole derivatives and pharmaceutical compositions containing them | |
| GB9407386D0 (en) | Pharmaceutical formulation | |
| GB9402203D0 (en) | Pharmaceutical formulation | |
| IL115563A0 (en) | Benzoxazole derivatives and pharmaceutical compositions containing the same | |
| IL115905A0 (en) | Sordarin derivatives their preparation and pharmaceutical compositions containing them | |
| GB9405856D0 (en) | Pharmaceutical formulation | |
| IL114572A0 (en) | Benzamine pharmaceutical compositions containing it its preparation and use | |
| GB9416599D0 (en) | Pharmaceutical formulation | |
| AP9600866A0 (en) | Benzamine derivative compositions containing said derivative and use thereof | |
| IL109275A0 (en) | 5-acylamino-1,2,4-thiadiazoles, their preparation and pharmaceutical compositions containing them | |
| IL116101A0 (en) | Benzamide its preparation and pharmaceutical compositions containing it | |
| IL110809A0 (en) | 1,5-diphenyl-3-pyrazolylalkyl-n-hydroxydithiocarbamates and pharmaceutical compositions containing them | |
| IL115272A0 (en) | Asp-pallidipin pharmaceutical compositions containing the same and processes for the preparation thereof | |
| IL113415A0 (en) | Dihydrodibenzoquinolinediones their preparation and use and pharmaceutical compositions containing them | |
| IL115982A0 (en) | Cyclolignan derivatives and pharmaceutical compositions containing the same | |
| IL116082A0 (en) | Oxazoles their preparation and pharmaceutical compositions containing them | |
| IL115981A0 (en) | Cyclolignan derivatives procosses for the preparation thereof and pharmaceutical compositions containing the same | |
| IL116504A0 (en) | 14, 17-C2-bridged steroids and pharmaceutical compositions containing the same | |
| IL116012A (en) | 6-Methoxy-1H- benzotriazole-5- carboxamide derivatives their preparation and pharmaceutical compositions containing them | |
| IL114161A0 (en) | Amido- quinoxalinediones pharmaceutical compositions containing them and their use | |
| EP0708654A4 (en) | HUMORAL THYMUS FACTOR GAMMA 2 (THF-GAMMA 2) ANALOGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | |
| IL94970A0 (en) | Fusidic acid derivatives and pharmaceutical compositions containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |